Es ist ein Fehler aufgetreten!
Merck Aktie
| 126.93 CHF | -1.75CHF | -1.36% |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.89 |
| Massachusetts Financial Services Co. | 4.91 |
| Amundi Asset Management SA (Investment Management) | 3.12 |
| Templeton Global Advisors Ltd. | 3.01 |
| Government Pension Fund - Global (the) | 1.98 |
| Vanguard Total International Stock Index Fund | 1.61 |
| American Funds Europacific Growth Fund | 1.30 |
| Templeton Growth Fund Inc. | 0.86 |
| Mfs Institutional International Equity Fund | 0.81 |
| Dws Aktien Strategie Deutschland | 0.70 |
| Dws Deutschland | 0.69 |
| Invesco Funds - Pan European Structured Equity Fund | 0.67 |
| Vanguard Developed Markets Index Fund | 0.62 |
| Ishares Dax (de) | 0.62 |
| Ftif Sicav - Growth (euro) Fund | 0.57 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| Personal am Ende des Jahres | 49'613 | 50'414 | 52'880 | 51'713 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.26 | 0.30 | 0.29 | 0.29 |
Bilanz (in Mio. EUR) - Aktiva
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| Summe Umlaufvermögen | 7'348 | 7'666 | 7'447 | 9'236 |
| Summe Anlagevermögen | 26'290 | 26'438 | 23'946 | 25'183 |
| Summe Aktiva | 38'787 | 39'002 | 36'063 | 37'403 |
Bilanz (in Mio. EUR) - Passiva
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 13'503 | 12'449 | 9'943 | 7'983 |
| Summe Fremdkapital | 25'931 | 24'952 | 21'997 | 20'170 |
| Summe Eigenkapital | 12'855 | 14'050 | 14'066 | 17'233 |
| Summe Passiva | 38'787 | 39'002 | 36'063 | 37'403 |
Adresse
| Frankfurter Strasse 250, 64293 Darmstadt | |
| Telefon | +49 (6151) 72-9880 |
| Fax | +49 (6151) 72-5962 |
| Internet | http://www.merck.de |
Management
|
Anand Nambiar
Global Head-Semiconductor Solutions |
|
Anne Lange
Member-Supervisory Board |
|
Belén Garijo López
Chief Executive Officer-Healthcare |
|
Christian Raabe
Member-Supervisory Board |
|
Constantin Fest
Head-Investor Relations |
|
Daniel Thelen
Member-Supervisory Board |
|
Dietmar Eidens
Head-Human Resources |
|
Dietmar Oeter
Member-Supervisory Board |
|
Dorothea Wenzel
Head-Controlling & Strategy |
|
Edeltraud Glänzer
Member-Supervisory Board |
|
Friederike Rotsch
Group General Counsel, Head-Legal & Compliance |
|
Gabriele Eismann
Member-Supervisory Board |
|
Heidi Fagerholm
Head-Advanced Technologies |
|
Helene von Roeder
Member-Supervisory Board |
|
Helga Rübsamen-Schaeff
Member-Supervisory Board |
|
Jürgen Glaser
Member-Supervisory Board |
|
Kai Beckmann
Chief Executive Officer-Performance Materials |
|
Marcus Kuhnert
Chief Financial Officer |
|
Maya Martinez-Davis
President-Biopharma Latin America |
|
Michael Fletterich
Vice Chairman-Supervisory Board |
|
Michael Heckmeier
EVP & Head-Business Unit Display Materials |
|
Michael Kleinemeier
Member-Supervisory Board |
|
Peter Emanuel Merck
Member-Supervisory Board |
|
Renate Koehler
Member-Supervisory Board |
|
Sascha Held
Member-Supervisory Board |
|
Simon Thelen
Member-Supervisory Board |
|
Stefan Oschmann
Chairman-Executive Board & CEO |
|
Udit Batra
Chief Executive Officer-Life Science |
|
Walter Galinat
Member-Executive Board |
|
Wolfgang Heinz Büchele
Chairman-Supervisory Board |
